• Biocon profit growth: Consolidated net profit surged more than fourfold, supported by strong growth in the biopharmaceutical business and reduced finance costs.
• Portfolio expansion: Biocon expects to add a couple of new products to its portfolio over the next one to two years.
• Patent expiry outlook: The company expects its next major wave of growth to materialize later as significant big-ticket molecules in the cancer and inflammation spaces come off patent.